Clinical Trial: Early Triple Lipid-Lowering Therapy With Bempedoic Acid After Acute Coronary Syndrome

U.S., Sept. 18 -- ClinicalTrials.gov registry received information related to the study (NCT07824323) titled 'Early Triple Lipid-Lowering Therapy With Bempedoic Acid After Acute Coronary Syndrome' on Sept. 11.

Brief Summary: This randomized clinical trial will evaluate whether starting bempedoic acid in addition to high-intensity statin therapy and ezetimibe within 72 hours after percutaneous coronary intervention improves low-density lipoprotein cholesterol (LDL-C) control in adults with acute coronary syndrome. Participants will receive either triple therapy with a high-intensity statin, ezetimibe, and bempedoic acid or standard dual therapy with a high-intensity statin and ezetimibe for 12 weeks. The primary outcome is the proportion of...